News

2016

January 11 BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease at 34th Annual J.P. Morgan Annual Healthcare Conference

2015

July 15 ProNAi Therapeutics Announces Pricing of Initial Public Offering
June 12 ProNAi Therapeutics Files Registration Statement for Proposed Initial Public Offering

2014

September 18 World’s First Integrated Delivery System Meets All Endpoints in the DIRECT II Randomized, Controlled Drug-Eluting Coronary Stent Study
June 29 The Eureka Index: Most innovative companies - 1. CytoPherx Inc., Ann Arbor
May 29 Svelte Medical Systems Announces Completion of 6-Month Follow-up in the DIRECT II Drug-Eluting Stent Study
May 27 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease
April 22 ProNAi Therapeutics closes on largest VC funding round in state history: $59.5M
April 21 ProNAi Therapeutics Raises $59.5 Million Series D Financing
March 10 West Health Investment Fund Joins Svelte Medical Systems Private Financing as Major Investor
January 13 ProNAi Therapeutics Secures $12 Million Series C Financing to Expand Phase II Cancer Studies for PNT2258, a Novel BCL2 Inhibitor, in Defined Lymphoma Patients

2013

December 9 ProNAi Therapeutics Reports Anti-Tumor Activity from Ongoing Phase II Clinical Study of PNT2258, a Novel BCL2-Inhibitor, at ASH Annual Meeting
November 14 Svelte Medical Systems Announces Enrollment Complete in the DIRECT II Drug- Eluting Stent Study
November 7 ProNAi to Present Phase II Clinical Data at ASH for PNT2258, a BCL2 Targeted Drug
October 31 Svelte Medical Systems Announces Raise of Additional $22M in Private Financing
October 18 Women of Power Series - Part One (miindia.com exclusive)
June 24 Upsher-Smith Announces Patient Enrollment in Open-Label Safety Study of USL261 (Intranasal Midazolam) for Rescue Treatment of Seizure Clusters in Epilepsy
May 23 Svelte Drug-Eluting Stent Utilizing New Class of Bioabsorbable Drug Coating Attains 0% Clinically-Driven Events Through 12-Months in First-In- Man Study

March 19

BioMarin to Advance BMN-701 for Pompe Disease to Next Phase (2/3) of Development
January 30 Svelte Medical Systems Announces Treatment of First Patient in the DIRECT II Drug- Eluting Stent Study
January 6 ProNAi raising VC to fund phase-two cancer studies, looks to possible sale

2012

November 9

ProNAi Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting
October 22
Svelte Medical Systems Announces FDA Approval to Initiate a Pivotal Study of Its Coronary Stent Integrated Delivery System (IDS)
October 10
Svelte Medical Hires Bayer Executive as New Leader
July 30
Asterand shareholders approve delisting
June 14
Svelte Medical Systems Announces Start of the FAASTER Post‐Market Registry Study
June 11
Asterand Plc Announces Proposed Disposal of Human Tissue Business
May 15
Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study
April 30
Asterand plc - Annual Report and Accounts 2011, Chairman's Statement
March 15
Smarticles Extend Their Reach In ProNAi’s DNAi Approach
January 4
CytoPherx Raises $34 Million to Move Into U.S. Clinical Trials

2011

November 9 Svelte Medical Systems offers All-In-One DES application
October 24 Asterand Plc Commencement of Formal Sales Process
August 31 Asterand Interim Results for the Period Ended 30 June 2011
July 17 With Robert Croce on Board, Svelte Medical Systems Raises $9.7M
May 17 Asterand plc Interim Management Statement
April 28 Asterand plc Final Results Statement for the year ended 31 December 2010
April 8 Transradial Wrist Angioplasty RIVALs Femoral
March 30 Svelte Medical Systems, Inc. Completes 6 month Follow-up With Its “All In One” Stenting System
March 16 From Human Tissue Supplier to R&D Contractor to BioBank Builder, Asterand Seeks Its Future
January 22 Just One Tiddler Can Prove Very Satisfying (Asterand)
January 20 BioMarin Commences BMN 701 Phase 1/2 Trial for Treatment of Pompe Disease

2010

November 3 Asterand Plc Interim Management Statement
October 1 National Cancer Institute Awards Contract to Asterand, Valued at Up to $24.3 Million
September 20 ProNAi Initiates Phase I Cancer Clinical Study of PNT2258
August 23 Svelte Medical Systems, Inc. Receives CE Mark Approval to Market the Svelte Acrobat Stent-on-a-Wire (SOAW) Coronary Stent System
August 17 BioMarin Acquires ZyStor Therapeutics, Inc.
June 28 Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline
June 18 U-M spin-off CytoPherx grows to 12 people / CytoPherx raises $5M to develop dialysis filters
May 13 Asterand Interim Management Statement
May 13 Michigan VC's Top Ten List
April 8 Svelte Medical Systems, Inc. Successfully concludes Series A financing
March 30 Asterand plc Preliminary Results Statement for the year ended 31 December 2009
March 30 Asterand - Taking it in Stride, Daniel Stewart & Co. 2009 full year results
January 8 Svelte Medical Systems, Inc. Announces the Initiation of its European Clinical Trial and the expansion of its Executive Management Team

2009

December 7 Svelte Medical Systems, Inc. Successfully Raises $6M in Private Funding
December 4 Svelte Medical Systems Named a Top Innovator Winner
November 18 Asterand Issues Interim Management Statement and Announces Agreement to Acquire BioSeek
November 9 Ikano Therapeutics Receives Orphan Drug Designation for Epilepsy Drug
October 14 ZyStor Cleared to Begin Clinical Trial
August 11 Kereos Article, Bee Venom Destroys Cancer Cells in Tests on Mice
June 30 Asterand plc Interim Results for the Period Ended 30 June 2009
May 11 Nephrion, Inc. Announces R. James Danehy as President and Chief Executive Officer
May 7 Triathlon Medical Hires Sooch, Eyes $150M Second Fund
May 5 Svelte Medical Systems, Inc. Licenses Stent Design and Delivery System Technology from Cordis Corporation
March 30 Asterand plc Preliminary Results Statement for the year ended 31 December 2008
March 13 Wide-ranging restructuring bears fruit for Asterand
March 3 Intranasal Becomes Ikano, Nabs $18M Series B
February 9 Asterand sees first yearly profit, wants acquisitions, partnership
January Asterand 2008 Share Performance

2008

November 11 Asterand Plc Interim Management Statement
August 27

Asterand to Enter Into Exclusive License Agreement with Allergan for Pre-Clinical Compounds Focused on Diseases of the Eye

July 8 Intranasal Therapeutics Names Jeffrey Edelson, MD, Executive Vice President, R&D and Chief Medical Officer
June 17 Asterand plc Board Appointments
May 19 Asterand plc Interim Management Statement
April 4 Asterand plc Announces Preliminary Results for 2007
April 2 Kereos Article, Nano-sized technology has super-sized effect on tumors
April The Fischell Family's Secret of Success
March 19 ProNAi Cleared to Begin Phase I Clinical Trials

2007

December 24 ProNAi: The Other Interference
October 18 Business Weekly-10 Questions to Asterand CEO Martyn Coombs
October 3 Asterand Awarded US Government Contract to Evaluate World’s Largest Tissue Repository
June 6 Asterand plc - Strategy Announcement
May 9 Asterand plc Annual General Meeting Statement 9 May, 2007
April 17 ProNAi Announces Preclinical Success For PNT2258 Therapeutic - Curative Events in Xenograft Mice For Difficult-To-Treat Non-Hodgkin's Lymphoma
April 4 ITI Appoints Pharmaceutical Industry Veteran, Peter F. Young, as President and CEO
March 27 Martyn Coombs Appointed As a Director and CEO of Asterand plc
March 6 ProNAi and Novosom AG Announce Collaboration to Enable Delivery of DNAi®-based Cancer Therapeutics
January 8 ProNAi Announces DNA Interference (DNAi®) Drug Development Strategy for 2007

2006

December 6 Intranasal Therapeutics, Inc. Adds Key Executives to Management Team
September 29 Published Data Shows Kereos Technology Specifically Targets Arterial Plaque
September 26 ProNAi Announces Executive Team Buildup and new CEO Richard Gill
September 25 Asterand Annouces 2006 Interim Trading Results
September 7 Renamed Biologics Secures $40M in Private Equity Financing
August 15 ITI Closes $39M Series A Venture Financing
July 31 Asterand Plc Annual Shareholders Meeting Statement and CEO Succession Plans
July 25 ITI Study shows Potential of IntraNasal Midazolam as Effective Sedative
May 11 Asterand offers new cell line to speed cancer research
April 17 Asterand Announces New Test to Reduce Risks in Human Drug Trials
March 28 RenaMed Biologics to Expand Operations to Westborough, MA
March 23 Gary Stroy Takes Helm At Neuralieve after Afmedica
March 20 Asterand PLC Announces Preliminary Results for 2005
March Positive Partnering - Apjohn Group Article at University of Minnesota
February 23 Asterand, Backed By State and WSU, Building World Bank For Human Tissue Samples
January 27 BTG Licenses Analgesic Compounds from Asterand

2005

December 13 Kereos Appoints Pfizer Veteran to Lead Pharmacology, also Announces New Directors
November 15 Kereos' Collaborators Present On Targeted Therapies For Cardiovascular Disease
November 12 RenaMed Biologics Reports Positive Phase II Data With Renal Bio-Replacement Therapy
October 19 ProNAi Raises $4.25M to Develop a New Class of Therapies That Target DNA
October 7 Angiotech Completes Acquisition of Afmedica
September 28 RenaMed Biologics and Genzyme Announce Worldwide Collaboration to Advance Treatment for Acute Renal Failure
September 20 Kereos Secures $19.5 Million in Series B Financing
September 19 Merger of Pharmagene and Asterand to Form Leading Company in Human Tissue Supply and Research Services
July 11 Michigan Drives For Biotech Industry, But The Road Can Be Bumpy
June 9 Human Tissue Co. Asterand Closes On $3.5M Series D
June 9 Detroit's Asterand Voted Best Place To Work For Scientists
April 18 Venture Michigan Fund Announces Fund Man as Credit Suisse First Boston
March 8 Grand Angels Go Biopharm, Local Group Invests In ProNAi Therapeutics, Inc.
March 7 Afmedica Press Release Announcing New CEO Gary Stroy
March 1 Asterand Becoming World Class Life Sciences Asset For Michigan
February 6 Impact Of Pfizer Acquisition Of Esperion Ripples Through Michigan Life Sciences Industry A Year Later

2004

December 15 Zystor Therapeutics Completes First Financing
June 21 Scientists Vote Detroit's Asterand "Best Place To Work."
April Michigan Business Report, Apjohn Creating Life Sciences Opportunities

2003

November 21 Asterand Raises Series "C" Financing
Copyright 2005 Apjohn Ventures